Status:
COMPLETED
Collect Clinical Data in Chinese Patients Received CUBICIN Treatment for Actual Usage in Clinical Practice
Lead Sponsor:
AstraZeneca
Conditions:
S. Aureus Bloodstream Infection
Eligibility:
All Genders
Brief Summary
This is a Multicenter, observational, non-interventional registry designed to collect clinical data in Chinese patients who have received CUBICIN treatment under condition of actual usage in clinical ...
Detailed Description
MC MD
Eligibility Criteria
Inclusion
- Patient has received CUBICIN treatment, decided by treating physician
- A patient who is considered as ethnic Chinese
- Provision of subject informed consent
Exclusion
- A patient record will not be eligible for the registry database if the patient received CUBICIN as part of a controlled clinical study for the current infection episode.
Key Trial Info
Start Date :
January 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2012
Estimated Enrollment :
203 Patients enrolled
Trial Details
Trial ID
NCT01212601
Start Date
January 1 2011
End Date
November 1 2012
Last Update
November 27 2012
Active Locations (18)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Beijing, Beijing Municipality, China
2
Research Site
Fuzhou, Fujian, China
3
Research Site
Xiamen, Fujian, China
4
Research Site
Zhangzhou, Fujian, China